HIV InfectionsPhase 3NCT00067782
A Phase IIIB Study Evaluating the Effect on Serum Lipids Following a Switch to Atazanavir in HIV Infected Subjects Evidencing Virologic Suppression on Their First PI-Based Antiretroviral Therapy
A Phase 3 study testing Atazanavir (immediate switch) and Atazanavir (Week 24 switch) in people with HIV Infections, run by Bristol-Myers Squibb at 19 sites in United States.
Trial summary
The purpose of this clinical research study is to learn if atazanavir is associated with serum LDL cholesterol in HIV-infected subjects following a substitution of atazanavir for their previously administered protease inhibitor. Read more about this study
- Who is it for?
- Ages 16 years and older
- Conditions the study is for
- HIV Infections
- What is being tested?
- Atazanavir (immediate switch) and Atazanavir (Week 24 switch)
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- Not given
- Where
- 19 sitesUnited States
- Study dates
- Dec 2002to Mar 2005
- Phase
- Phase 3
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 16 years and older
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Who may be able to join
- Must be on current HIV treatment regimen at least 3 to 6 months prior to study (this must be one protease inhibitor, or ritonavir-boosted protease inhibitor, and two nucleoside reverse transcriptase inhibitors) must be subject's first PI ever received
- Plasma HIV-1 RNA level < 50 c/mL within 3 to 6 months prior to study start
- Fasting LDL cholesterol > 130 mg/dL
- Prisoners or subjects involuntary incarcerated for treatment of psychiatric or physical illness
Who cannot join
- WOCBP who do not use effective barrier contraception for any reason
- Women who are pregnant or breast feeding
- A life expectancy < 12 months
- Presence of a newly diagnosed HIV-related OI or any medical condition requiring acute therapy at the time of enrollment
- Cushing's Syndrome
- Uncontrolled diabetes mellitus, history of diabetic ketoacidosis or hyperosmolar syndrome
Show all 30Show fewer
- Untreated hypothyroidism or hyperthyroidism
- Nephrotic syndrome or significant proteinuria
- Obstructive liver disease
- Active alcohol or substance abuse
- Proven or suspected acute hepatitis in the 30 days prior to study entry
- Intractable diarrhea (greater than or equal to 6 loose stools/day for at least 7 consecutive days) within 30 days prior to study start
- History of acute or chronic pancreatitis
- Inability to swallow capsules
- Presence of cardiomyopathy
- Known history of prolonged QTc interval
- Any of the following:
- clinical symptoms potentially related to heart block
- heart rate < 40 bpm
- any of the following EKG abnormalities:
- pause length > 3 seconds ii) second or third degree AV heart block iii) QTc interval > 450 msec for males iv) QTc interval > 470 msec for females
- Fasting serum triglyceride level > 750 mg/dL
- Any of the following lab values within 2 weeks of starting study drug:
- serum creatinine greater to or equal to 1.5 times the upper limit of normal
- total serum lipase greater than or equal to 1.4 times the upper limit of normal
- liver transaminases greater than or equal to 3 times the upper limit of normal
- total serum bilirubin greater than or equal to 1.5 times the upper limit of normal
- Hypersensitivity to any component of the formulation of study drug
- Use of any lipid-lowering agent within 4 weeks prior or during study
- Use of a PI-containing ARV regimen prior to entry which is comprised of more than one PI
Trial locations and contacts
19 sites in 1 country.
19 sites in 1 country
United States19 sites
Local Institution
Altamonte Springs, Florida
Local Institution
Boston, Massachusetts
Local Institution
Cleveland, Ohio
Local Institution
Columbia, South Carolina
Local Institution
East Orange, New Jersey
Local Institution
Fort Lauderdale, Florida
Local Institution
Fort Worth, Texas
Local Institution
Houston, Texas
Local Institution
Huntersville, North Carolina
Local Institution
Miami, Florida
Local Institution
Minneapolis, Minnesota
Local Institution
New York, New York
Local Institution
Oklahoma City, Oklahoma
Local Institution
Philadelphia, Pennsylvania
Local Institution
Phoenix, Arizona
Local Institution
St Louis, Missouri
Local Institution
Tampa, Florida
Local Institution
Washington D.C., District of Columbia
Local Institution
West Hollywood, California
About this study
The purpose of this clinical research study is to learn if atazanavir is associated with serum LDL cholesterol in HIV-infected subjects following a substitution of atazanavir for their previously administered protease inhibitor.
- Conditions
- HIV Infections
- Being tested
- Atazanavir (immediate switch), Atazanavir (Week 24 switch)
- Keywords
- HIV, Treatment Experienced
- Medical subject headings
- HIV Infections
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Atazanavir (immediate switch)Drug
Also called Reyataz
Capsules, Oral, 400mg, Once daily, 48 weeks.
Atazanavir (Week 24 switch)Drug
Also called Reyataz
Capsules, Oral, 400mg, Once daily, 48 weeks.
| Study group | Role | What they receive |
|---|---|---|
| 1 | Active comparator | Not described Receives: Drug: Atazanavir (immediate switch) |
| 2 | Active comparator | Not described Receives: Drug: Atazanavir (Week 24 switch) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Time to virologic rebound for subjects with HIV RNA < 50 c/mL at baseline; Magnitude/ durability of increases from baseline in absolute CD4 (Time-Averaged Difference) through WK12; Mean % change from baseline in fasting LDL cholesterol at WK12.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted28 Aug 2003 (estimated)
- Study startDec 2002
- Primary completionMar 2005
- Study completionMar 2005
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for HIV InfectionsStudies of the same condition, open and under way.
- More trials run by Bristol-Myers SquibbThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
Sponsor and investigators
- Lead sponsor
- Bristol-Myers Squibb
- Sponsor type
- Industry (pharma, biotech, devices)
- Investigators
- Bristol-Myers Squibb, Study director, Bristol-Myers Squibb
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00067782
- Sponsor's protocol ID
- AI424-067
- Status last verified
- Jan 2010
- First submitted
- 27 Aug 2003
- Last updated
- 14 Apr 2011
- Results posted
- No
Study at a glance
From the registry record, last updated by the sponsor on 14 Apr 2011. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase IIIB Study Evaluating the Effect on Serum Lipids Following a Switch to Atazanavir in HIV Infected Subjects Evidencing Virologic Suppression on Their First PI-Based Antiretroviral Therapy
- ClinicalTrials.gov ID
- NCT00067782
- Acronym / sponsor ID
- AI424-067
- Conditions
- HIV Infections
- Keywords
- HIV, Treatment Experienced
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Completed
- Lead sponsor
- Bristol-Myers SquibbIndustry (pharma, biotech, devices)
- Study start
- Dec 2002
- Primary completion
- Mar 2005 (actual)
- Study completion
- Mar 2005 (actual)
- First posted
- 28 Aug 2003 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this clinical research study is to learn if atazanavir is associated with serum LDL cholesterol in HIV-infected subjects following a substitution of atazanavir for their previously administered protease inhibitor.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| 1 | Active comparator | Drug: Atazanavir (immediate switch) |
| 2 | Active comparator | Drug: Atazanavir (Week 24 switch) |
Who may qualify
- Ages
- 16 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (4 listed)
- Must be on current HIV treatment regimen at least 3 to 6 months prior to study (this must be one protease inhibitor, or ritonavir-boosted protease inhibitor, and two nucleoside reverse transcriptase inhibitors) must be subject's first PI ever received
- Plasma HIV-1 RNA level < 50 c/mL within 3 to 6 months prior to study start
- Fasting LDL cholesterol > 130 mg/dL
- Prisoners or subjects involuntary incarcerated for treatment of psychiatric or physical illness
Key exclusion criteria (30 listed)
- WOCBP who do not use effective barrier contraception for any reason
- Women who are pregnant or breast feeding
- A life expectancy < 12 months
- Presence of a newly diagnosed HIV-related OI or any medical condition requiring acute therapy at the time of enrollment
- Cushing's Syndrome
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Atazanavir (immediate switch)Also: ReyatazCapsules, Oral, 400mg, Once daily, 48 weeks. | Drug | 1 |
| Atazanavir (Week 24 switch)Also: ReyatazCapsules, Oral, 400mg, Once daily, 48 weeks. | Drug | 2 |
Primary outcome
Time to virologic rebound for subjects with HIV RNA < 50 c/mL at baseline; Magnitude/ durability of increases from baseline in absolute CD4 (Time-Averaged Difference) through WK12; Mean % change from baseline in fasting LDL cholesterol at WK12.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 Apr 2011.
Related trials for HIV Infections
RecruitingObservational study
Olfactory Function and Model-Based Behavior in People Living With HIV and SUD
HIV, Substance Use Disorder
RecruitingPhase 2
Multiple Interventions With Distinct Anti-reservoir Activities in People on Antiretroviral Treatment
HIV - Human Immunodeficiency Virus
RecruitingPhase 2
CASCADE 2002: PROTECT Study, "PRObiotics to TrEat Anal preCancer Trial
HSIL, High Grade Squamous Intraepithelial Lesion, HPV-Related Squamous Cell Carcinoma
Recruiting
Improving Engagement in HIV and Cancer Care in Zimbabwe
Cancer, HIV
RecruitingObservational study
Clinical and Immunologic Monitoring of Patients With Known or Suspected HIV Infection
HIV
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Bristol-Myers Squibb study director
Bristol-Myers Squibb
19 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Atazanavir (immediate switch) and Atazanavir (Week 24 switch) in people with HIV Infections, run by Bristol-Myers Squibb at 19 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 30 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 14 Apr 2011. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 19 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Time to virologic rebound for subjects with HIV RNA < 50 c/mL at baseline; Magnitude/ durability of increases from baseline in absolute CD4 (Time-Averaged Difference) through WK12; Mean % change from baseline in fasting LDL cholesterol at WK12.. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Apr 2011.